索拉非尼联合华蟾素片治疗中晚期原发性肝癌的临床疗效观察  

Clinical observation of patients with primary liver cancer treated by sorafenib combined cinobufagin tablets

作　　者：冯丽华[1] 陈毅德[1] 郑志高[1] 高应勤[1] 

机构地区：[1]厦门市第二医院肿瘤内科,福建厦门361000

出　　处：《中国癌症杂志》2012年第11期856-859,共4页China Oncology

摘　　要：背景与目的:索拉非尼目前已广泛应用于中晚期肝癌的治疗,同时中成药华蟾素在肝癌的辅助治疗中也起到了一定作用。本文观察口服索拉非尼联合华蟾素片治疗中晚期原发性肝癌的临床疗效、不良反应、生活质量及疼痛情况。方法:选择2009年1月—2012年7月经我院确诊为中晚期原发性肝癌的59例患者,随机分成索拉非尼联合华蟾素片治疗组(联合组,n=30)与索拉非尼单药对照组(对照组,n=29)。联合组给予索拉非尼400 mg,每日2次,华蟾素片4片,每日3次;对照组给予单药索拉非尼400 mg,每日2次。4周为1个治疗周期,每两个治疗周期后行MRI等检查评价疗效。结果:临床疗效方面,联合组临床获益率(clinical benefit rate,CBR)明显高于对照组,差异有统计学意义(P<0.05);不良反应方面,联合组腹泻率较对照组高,但差异无统计学意义(P>0.05),未见其他明显增加的不良反应;联合组治疗后白细胞(white blood cell,WBC)、总胆红素(total bilirubin,TBIL)和谷丙转氨酶(alanine aminotransferase,ALT)指标较对照组有明显的改善,差异有统计学意义(P<0.05);在生活质量方面,联合组生活质量改善率明显高于对照组,两组比较差异有统计学意义(P<0.05);在疼痛方面,联合组疼痛缓解率明显高于对照组,差异有统计学意义(P<0.05)。结论:索拉非尼联合华蟾素片是中晚期肝癌一种较理想的治疗选择。Background and purpose： Sorafenib has been widely used in the treatment of middle-advanced stage liver cancer. At the same time, cinobufagin of traditional Chinese medicines also played an important role in the treatment of liver cancer. Our study was designed to observe the clinical efficacy, adverse effects, quality of life and the pain of patients when sorafenib combined with cinobufagin tablets in the treatment of middle-advanced primary liver cancer. Methods： From Jan. 2009 to Jul. 2012, 59 patients with middle-advanced stage liver cancer were randomly divided into treatment group which treated 30 patients by sorafenib combined with cinobufagin tablets, and control group which treated 29 patients by sorafenib only. Results： The clinical benefit rate （CBR） of the treatment group was better than that of control group, the difference was significant （P〈0.05）. The diarrhea rate of the treatment group was higher than that of control group, but there were no significant differences （P〉0.05）. There was no significant increase in the rate of other adverse effects. The WBC, TBIL, ALT indicator were improved obviously in the control group, the difference was significant P〈0.05）. The life quality of patients in treatment group were improved more significantly than those in control group （P〈0.05）. Cancer pain relief rate in treatment group was significantly higher than that in control group （P〈0.05）. Conclusion： Sorafenib combined with cinobufagin tablets in the treatment of liver cancer, is a good choice for treatment of middle-advanced liver cancer.

关 键 词：索拉非尼 华蟾素片 原发性肝癌 临床疗效 

分 类 号：R735.7[医药卫生—肿瘤]